NPM1-Mutation-Based Measurable Residual Disease Assessment after Completion of Two Courses of Post-remission Therapy Is a Valuable Clinical Predictor of the Prognosis of Acute Myeloid Leukemia

By
Justin.choi
-
0
210
Scientists investigated the optimal timing and cutoff value to ascertain the value of NPM1 mutation in measurable residual disease assessment.
[International Journal of Hematology]
Abstract